These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37169384)

  • 1. Heterogeneity of treatment effects by risk in pulmonary arterial hypertension.
    Pan HM; McClelland RL; Moutchia J; Appleby DH; Fritz JS; Holmes JH; Minhas J; Palevsky HI; Urbanowicz RJ; Kawut SM; Al-Naamani N
    Eur Respir J; 2023 Jul; 62(1):. PubMed ID: 37169384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BMI and Treatment Response in Patients With Pulmonary Arterial Hypertension: A Meta-analysis.
    McCarthy BE; McClelland RL; Appleby DH; Moutchia JS; Minhas JK; Min J; Mazurek JA; Smith KA; Fritz JS; Pugliese SC; Urbanowicz RJ; Holmes JH; Palevsky HI; Kawut SM; Al-Naamani N
    Chest; 2022 Aug; 162(2):436-447. PubMed ID: 35247393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is low-risk status a surrogate outcome in pulmonary arterial hypertension? An analysis of three randomised trials.
    Blette BS; Moutchia J; Al-Naamani N; Ventetuolo CE; Cheng C; Appleby D; Urbanowicz RJ; Fritz J; Mazurek JA; Li F; Kawut SM; Harhay MO
    Lancet Respir Med; 2023 Oct; 11(10):873-882. PubMed ID: 37230098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Long-Term Oral Bosentan in Different Types of Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis.
    Kuang HY; Li Q; Du HA; Chen M; Yin YH
    Am J Cardiovasc Drugs; 2021 Mar; 21(2):181-191. PubMed ID: 32918210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Treatment Response in Idiopathic and Connective Tissue Disease-associated Pulmonary Arterial Hypertension.
    Rhee RL; Gabler NB; Sangani S; Praestgaard A; Merkel PA; Kawut SM
    Am J Respir Crit Care Med; 2015 Nov; 192(9):1111-7. PubMed ID: 26291092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enrichment Benefits of Risk Algorithms for Pulmonary Arterial Hypertension Clinical Trials.
    Scott JV; Garnett CE; Kanwar MK; Stockbridge NL; Benza RL
    Am J Respir Crit Care Med; 2021 Mar; 203(6):726-736. PubMed ID: 32937078
    [No Abstract]   [Full Text] [Related]  

  • 7. Minimal Clinically Important Difference in the 6-minute-walk Distance for Patients with Pulmonary Arterial Hypertension.
    Moutchia J; McClelland RL; Al-Naamani N; Appleby DH; Blank K; Grinnan D; Holmes JH; Mathai SC; Minhas J; Ventetuolo CE; Zamanian RT; Kawut SM
    Am J Respir Crit Care Med; 2023 Apr; 207(8):1070-1079. PubMed ID: 36629737
    [No Abstract]   [Full Text] [Related]  

  • 8. Pulmonary arterial hypertension treatment: an individual participant data network meta-analysis.
    Moutchia J; McClelland RL; Al-Naamani N; Appleby DH; Holmes JH; Minhas J; Mazurek JA; Palevsky HI; Ventetuolo CE; Kawut SM
    Eur Heart J; 2024 Jun; 45(21):1937-1952. PubMed ID: 38416633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do Patients With Low-Risk Pulmonary Arterial Hypertension Really Benefit From Upfront Combination Therapy?: Insight From the AMBITION Trial.
    Fauvel C; Liu Y; Correa-Jaque P; Kanwar MK; Vizza CD; Lin S; Benza RL
    Chest; 2023 Dec; 164(6):1518-1530. PubMed ID: 37356711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis.
    Frost AE; Badesch DB; Miller DP; Benza RL; Meltzer LA; McGoon MD
    Chest; 2013 Nov; 144(5):1521-1529. PubMed ID: 23907471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
    Hoeper MM; Al-Hiti H; Benza RL; Chang SA; Corris PA; Gibbs JSR; Grünig E; Jansa P; Klinger JR; Langleben D; McLaughlin VV; Meyer GMB; Ota-Arakaki J; Peacock AJ; Pulido T; Rosenkranz S; Vizza CD; Vonk-Noordegraaf A; White RJ; Chang M; Kleinjung F; Meier C; Paraschin K; Ghofrani HA; Simonneau G;
    Lancet Respir Med; 2021 Jun; 9(6):573-584. PubMed ID: 33773120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
    Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N
    Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial.
    Fischer A; Denton CP; Matucci-Cerinic M; Gillies H; Blair C; Tislow J; Nathan SD
    Respir Med; 2016 Aug; 117():254-63. PubMed ID: 27492539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostacyclin for pulmonary arterial hypertension.
    Barnes H; Yeoh HL; Fothergill T; Burns A; Humbert M; Williams T
    Cochrane Database Syst Rev; 2019 May; 5(5):CD012785. PubMed ID: 31042010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dynamics of the clinical functional and hemodynamic profile of patients with pulmonary arterial hypertension with initial monotherapy with endothelin receptor antagonists: bosentan vs. macitentan].
    Martynyuk TV; Aleevskaya AM
    Kardiologiia; 2020 Aug; 60(7):28-35. PubMed ID: 33155938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early decline in six-minute walk distance from the time of diagnosis predicts clinical worsening in pulmonary arterial hypertension.
    Huang J; Mehta S; Mura M
    Respiration; 2015; 89(5):365-73. PubMed ID: 25791910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
    McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W
    J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline Sex Differences in Pulmonary Arterial Hypertension Randomized Clinical Trials.
    Ventetuolo CE; Moutchia J; Baird GL; Appleby DH; McClelland RL; Minhas J; Min J; Holmes JH; Urbanowicz RJ; Al-Naamani N; Kawut SM
    Ann Am Thorac Soc; 2023 Jan; 20(1):58-66. PubMed ID: 36053665
    [No Abstract]   [Full Text] [Related]  

  • 19. A prospective study of the 6 min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naïve systemic sclerosis-associated pulmonary arterial hypertension.
    Sanges S; Launay D; Rhee RL; Sitbon O; Hachulla É; Mouthon L; Guillevin L; Rottat L; Montani D; De Groote P; Cottin V; Magro P; Prévot G; Bauer F; Bergot E; Chabanne C; Reynaud-Gaubert M; Leroy S; Canuet M; Sanchez O; Gut-Gobert C; Dauphin C; Pison C; Boissin C; Habib G; Clerson P; Conesa F; Cordier JF; Kawut SM; Simonneau G; Humbert M
    Ann Rheum Dis; 2016 Aug; 75(8):1457-65. PubMed ID: 26324844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Directing therapy in pulmonary arterial hypertension using a target 6 min walk distance.
    Porhownik NR; Myers R; Bshouty Z
    Can Respir J; 2013; 20(2):111-5. PubMed ID: 23616968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.